Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Investor Presentation (April 2012)
32 slides from Inovio Pharmaceuticals's investor presentation, Apr 13, 2012
Slide 1: Revolutionizing Vaccines
revolutionizing vaccines J. Joseph Kim, Ph.D. CEO April 13, 2012 NYSE Amex: INO
Slide 2: Forward Looking Statement
Forward Looking Statement Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s tech
Slide 3: Inovio: Revolutionizing Vaccines
Inovio: Revolutionizing Vaccines • Inovio’s synthetic vaccine technology designed to: • Treat some of today’s most challenging diseases • Universally protect against changing infectious disease strains • Break the body’s tolerance of cancerous cells • Targeting therapeutic markets with unmet needs a
Slide 4: Conventional Vaccines
Conventional Vaccines Increased life expectancy • Saved millions from sickness/death • Added decades to life expectancy • Deliver a virus or part of a virus to expose a unique antigen (foreign protein) • Generate antibodies that prevent targeted diseases from infecting cells • Low hanging fruit pick
Slide 5: Inovio's SynCon Synthetic Vaccines
Inovio’s SynCon® Synthetic Vaccines • Pushing the frontiers - new approach to vaccine design, formulation, manufacturing, and delivery • SynCon® “designer vaccines” give the body only the DNA instructions enabling its cells to produce the targeted antigen - nothing more • Generate powerful T-cells t
Slide 6: SynCon Universal Vaccine Design
SynCon® Universal Vaccine Design Immune responses more cross-reactive (universal) than those induced by single-strain vaccines Page 6
Slide 7: Superior Vaccine Delivery Using Electroporation
Superior Vaccine Delivery Using Electroporation Page 7
Slide 8: Inovio Electroporation (EP) Technology & Devices
Inovio Electroporation (EP) Technology & Devices • Efficient & effective vaccine delivery • 100X increase in immune responses • Far stronger T-cell immune responses than viral vectors • Safe and tolerable • No unwanted immune response • No residual carrier/vector causing toxicity • Delivery into mus
Slide 9: Better Delivery = Improved Immune Responses
Better Delivery = Improved Immune Responses Intramuscular Intradermal Display of green fluorescence protein (GFP) gene expression after electroporation delivery into rabbit muscle Page 9
Slide 10: Inovio's Strategy
Inovio’s Strategy • Advance/validate SynCon® + electroporation platform • Best in-class immunogenicity established in human studies • Develop proprietary products through proof-of-concept human data • Increase platform/product value through clinical validation • Maximize non-dilutive third party fun
Slide 11: Inovio Product Pipeline: Cancers
Inovio Product Pipeline: Cancers Pre- Indication Product (Antigen) Phase I Phase II Partner/Funding Milestone clinical Cervical Dysplasia VGX-3100 (E6/E7 2H 2013 Therapeutic Type 16/18 HPV) Phase II study data (Wilms’ tumor University of 2H 2012 Leukemia Cancers gene 1) Southampton Interim Phase II
Slide 12: Inovio Product Pipeline: Infectious Diseases
Inovio Product Pipeline: Infectious Diseases Pre- Indication Product (Antigen) Phase I Phase II Partner/Funding Milestone clinical 2H 2012 (NS3/4A) + SOC ChronTech Phase II interim data Hepatitis C Virus Therapy 2H 2012 INO-8000 VGX Inter/ (NS3/4A, NS4B, NS5A) PA CARE Grant Launch Phase I HIV Vaccin
Slide 13: VGX-3100: Cervical Dysplasia/Cancer Therapy
VGX‐3100: Cervical Dysplasia/Cancer Therapy • Cervical cancer • 99% caused by human papillomavirus (HPV) • Second leading cancer killer in women worldwide • ~500,000 new cases of cervical cancer annually • Cervical dysplasias (CIN) preceding cancer (U.S. annually) • CIN 1: 1.4 M • CIN 2/3: 300,000 •
Slide 14: VGX-3100 Phase I Study
VGX‐3100 Phase I Study • Design • 18 patients • 3 dose levels (0.3, 1.0 & 3.0 mg/each of 2 plasmids) • 3 vaccinations (months 0, 1 & 3) via EP delivery • Results • Vaccine safe and well-tolerated • Positive T-cell immune responses • Most robust generated by a DNA vaccine in humans • Stronger respons
Slide 15: VGX-3100: Phase I Study Data
VGX‐3100: Phase I Study Data T cell responses by other vaccines Low Dose Mid Dose High Dose All Groups • Strong T-cell response in 14 of 18 (78%) vaccinated subjects at month 4 • Durable responses: 12 of 13 responders (92%) displayed persistent, strong T-cell responses at month 9 • After 4th vaccina
Slide 16: VGX-3100: Phase II Study
VGX‐3100: Phase II Study • Randomized, blinded, placebo controlled • Up to 25 sites in 5 countries • 148 patients with CIN 2/3 + HPV 16/18 • Three vaccinations over 3 months, 6 months monitoring • 1˚endpoint: CIN 2/3 lesion clearance at month 9 • Initiated Q1 2011; enrollment ongoing • Efficacy data
Slide 17: Leukemia Vaccine: CML & AML
Leukemia Vaccine: CML & AML • Chronic myeloid leukemia (CML) 300,000+ new cases • Acute myeloid leukemia (AML) 222,000 deaths each year • Vaccine coded for Wilms’ tumor gene 1 (WT1) • Overexpressed in majority of acute leukemias • WT1 without EP in humans for other cancers modest CD8+ T-cells and me
Slide 18: Leukemia Vaccine: Phase II Study
Leukemia Vaccine: Phase II Study • Study design • Open label phase II clinical trial • Active: 37 CML patients, 37 AML patients • Control group: 100-110 AML/CML patients, non-vaccinated • 1˚ endpoints • CML: molecular response to disease marker (BCR-ABL) • AML: time to disease progression • Initiate
Slide 19: ChronVac-C Therapeutic Vaccine
ChronVac‐C® Therapeutic Vaccine • Hepatitis C virus (HCV) • Most common chronic blood-borne infection in the U.S. • 3.5 million chronically infected in U.S.: ~300 million worldwide • ~8,000 to 10,000 deaths annually from liver disease caused by HCV • Positive phase I study outcomes (HCV Genotype 1)
Slide 20: ChronVac-C Phase II Study
ChronVac‐C® Phase II Study • Open label, randomized phase II study in Sweden • 32 treatment-naïve subjects w/chronic HCV (genotype-1) • Active (n=20): 2 vaccinations ChronVac-C via EP + SOC • Control (n=12): SOC only • 1˚ endpoints • RVR (4 weeks) • Partial early viral response (pEVR) (12 weeks) • I
Slide 21: PENNVAX Global HIV Vaccine Program
PENNVAX® Global HIV Vaccine Program • SynCon® PENNVAX DNA vaccines target HIV gag, pol, and env proteins • Env protein determines clades (subtypes) PENNVAX-G/ PENNVAX-GP Coverage: Clades A, C, D PENNVAX-B Coverage: Clade B Page 21
Slide 22: PENNVAX-B: Phase I Studies
PENNVAX‐B: Phase I Studies • Preventive, randomized, placebo-controlled: run by HVTN • Three vaccinations over 3 months; 48 vaccinated subjects, 3 arms: • 1 mg PENNVAX-B (n=10) • 1 mg PENNVAX-B + DNA IL-12 delivered via EP (n=30) • Placebo (n=8) • T-cell immune responses superior to all other previo
Slide 23: SynCon Universal Influenza Vaccines
SynCon® Universal Influenza Vaccines • Targets critical sub-types • 100% protection in mice and ferrets against H5N1 & H1N1 challenge • H5N1 phase I interim data: Strong T-cells and antibodies in 72% and 96% of subjects w/ intramuscular delivery • Intradermal boost achieved 4X increase in HAI titers
Slide 24: Experienced Management Team
Experienced Management Team J. Joseph Kim, Ph.D., President & CEO • Decades of biotechnology/pharma management; ex-Merck; hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D Peter Kies, CFO • Ex-Ernst & Young; experience with growth companies Niranjan Y. Sardesai, Ph.D., COO • Extensive
Slide 25: Board of Directors
Board of Directors Avtar Dhillon, M.D., Chairman, BOD J. Joseph Kim, Ph.D. • Previously President & CEO, Inovio • President & CEO, Inovio Simon X. Benito Adel Mahmoud, Ph.D. • Retired Senior Vice President, Merck • Professor, Princeton University Vaccine Division • Retired President, Merck Vaccines
Slide 26: Scientific Advisory Board
Scientific Advisory Board David B. Weiner, Ph.D., Chairman, SAB Anthony W. Ford-Hutchinson, Ph.D. • “Father of DNA vaccines” • Former SVP, Vaccines R&D, Merck • Dept. of Pathology & Laboratory • Oversaw development: Singulair®, Medicine, U of PA Januvia®, Gardasil®, Zostavax®, Proquad® and Rotateq®
Slide 27: Financial Information
Financial Information Cash & short term investments1 $30.3 M Debt1 0M Burn rate ~$4.5 M/Q Cash runway 3Q 2013 Listing NYSE Amex: INO Issued & outstanding shares1 134.9 M Recent price2 $0.64 Market cap2 $86 M 1 Dec. 31, 2011 2 Mar. 23, 2012 Page 27
Slide 28: Investment Summary
Investment Summary • Paradigm shifting synthetic vaccine platform displaying best-in-class immunogenicity and other characteristics significantly improving upon conventional and new competitive vaccine technologies • Strong management team with vast vaccine discovery & development expertise • Health
Slide 29: Revolutionizing Vaccines
revolutionizing vaccines Investor Contact: Bernie Hertel Senior Director, Corporate Communications 858-410-3101 ● bhertel@inovio.com NYSE Amex: INO www.inovio.com
Slide 30: Multiple DNA Optimization Approaches
Multiple DNA Optimization Approaches Optimization per gene: • Computer designed immunogens based on Con hypothesis using early transmitter phenotype framework • Changes: synthetic high AT low GC leader which is highly efficient at targeting the antigens to the cell membrane • Species specific codon
Slide 31: VGX-3100: T-Cell Response Comparison
VGX‐3100: T‐Cell Response Comparison Investigational No. of Study Duration (Time to T cell response Clinical Outcome Vaccine Vaccinations Final Immunization) magnitude# Phase I trial – DNA1 3 3 months 0 - 25 no efficacy data 47% with complete regression Peptide2,3 3-4 2-3 months 7 - 19 of VIN3* 50%
Slide 32: T-Cell Responses: PENNVAX-B vs Other HIV Vaccines
T‐Cell Responses: PENNVAX‐B vs Other HIV Vaccines # of Study Duration (Time to % CD8 Vaccine Vaccina % CD4 Response Final Immunization) Response tions DNA Alone2,5 3-4 Up to 245 days 19-57 4-14 Vector -basedVaccine 4-5 Up to 210 days 7-54 3-50 (Ad5, Ad35, MVA, etc)3,4 Prime/Boost (DNA/Ad, DNA/MVA, 4
Inovio Pharmaceuticals — Investor Presentation (April 2012) on 6ix